objective metaanalysis of randomized controlled trials rctsof a hip powder of rosa canina rosehip preparation for symptomatic treatment of osteoarthritis oa in order to estimate the empirical efficacy as a pain reducing compoundmethod rcts from systematic searches were included if they explicitly stated that oa patients were randomized to either rosehip or placebothe primary outcome was reduction in pain calculated as effect size es defined as the standardized mean difference smdas secondary analysis the number of responders to therapy was analyzed as odds ratios or and expressed as the number needed to treat nntrestricted maximum likelihood reml methods were applied for the metaanalyses using mixed effects modelsresults the three studies 287 patients and a median trialduration of 3 monthsall supported by the manufacturer hybenvital internationalshowed a reduction in pain scores by rosehip powder 145 patients compared to placebo 142 patients es of 037 95 confidence interval ci 013060 p0002test for homogeneity seemed to support that the efficacy was consistent across trials i20thus it seems reasonable to assume that the three studies were measuring the same overall effectit seemed twice as likely that a patient allocated to rosehip powder would respond to therapy compared to placebo or219 p00009 corresponding to a nnt of six 95 ci 413 patientsconclusions although based on a sparse amount of data the results of the present metaanalysis indicate that rosehip powder does reduce pain accordingly it may be of interest as a nutraceutical although its efficacy and safety need evaluation and independent replication in a future largescalelongterm trial